PGP and cancer: It is remarkable that the comparative efficacy and safety of apixaban and dalteparin was not different in participants in CARAVAGGIO who were or were not concomitantly given anti-cancer agents (around 60% and 40%, respectively) [41], even though therapy with P-gp modulators is not a criterion to modify the dose of apixaban.